RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Fusion Pharmaceuticals Revenue 2024

Fusion Pharmaceuticals Revenue

528,360 USD

Fusion Pharmaceuticals Dividend yield

Ticker

FUSN

ISIN

CA36118A1003

In 2024, Fusion Pharmaceuticals's sales reached 528,360 USD, a -74.45% difference from the 2.07 M USD sales recorded in the previous year.

The Fusion Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e335.49-
2028e51.02-
2027e0.58-
2026e9.04-
2025e0.59-
2024e0.53-
20232.07-
20221.46-
20211.44-
2020--
2019--
2018--
2017--

Fusion Pharmaceuticals Aktienanalyse

What does Fusion Pharmaceuticals do?

Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development of innovative cancer therapies. The company was founded in Canada in 2014 and has since pursued a unique approach to cancer treatment: targeted radiation therapy. Fusion Pharmaceuticals' business model is based on providing cancer patients with an effective and gentle alternative to conventional treatment methods. The company utilizes a novel technology that allows radioisotopes to be specifically targeted to cancer cells. This enables radiation to be applied directly to the affected areas without damaging healthy tissue. Fusion Pharmaceuticals specializes in the development of therapies for solid tumors. The company collaborates with various partners to offer a wide range of treatment options. The key products currently include: - FP-1001: This product is currently in Phase 1 clinical trials and is intended for the treatment of patients with solid tumors. FP-1001 combines a specific antibody molecule with the radioactive isotope Actinium-225 to selectively destroy cancer cells. - FP-2000: This product is currently in the preclinical phase and aims to provide an effective treatment for pancreatic cancer. FP-2000 combines a specific antibody molecule with the radioactive isotope Lutetium-177 and has the potential to improve the survival rate of patients with this severe disease. - FP-3000: This product is also in the preclinical phase and is intended for the treatment of prostate cancer. FP-3000 combines a specific antibody molecule with the radioactive isotope Copper-67 and has the potential to offer an effective alternative to conventional treatments such as chemotherapy. Fusion Pharmaceuticals has rapidly gained importance in recent years and has attracted numerous prestigious investors. These include Canadian investment firm OrbiMed Advisors LLC and renowned US biotechnology company Johnson & Johnson. The company has also received several awards, including the Innovation Award from the Canadian government in 2019. For the future, Fusion Pharmaceuticals plans to further expand its development pipeline and create new therapies for a wide range of cancer diseases. The company aims to provide cancer patients worldwide with new hope and an effective alternative to conventional treatment methods. Fusion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Fusion Pharmaceuticals's Sales Figures

The sales figures of Fusion Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Fusion Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Fusion Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Fusion Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Fusion Pharmaceuticals Stock

How much revenue did Fusion Pharmaceuticals generate this year?

Fusion Pharmaceuticals has achieved a revenue of 528,360 USD this year.

How much was the turnover of the company Fusion Pharmaceuticals compared to the previous year?

The revenue of Fusion Pharmaceuticals has increased by -74.45% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Fusion Pharmaceuticals?

The revenue of Fusion Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Fusion Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Fusion Pharmaceuticals so important for investors?

The revenue of Fusion Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Fusion Pharmaceuticals pay?

Over the past 12 months, Fusion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharmaceuticals?

The current dividend yield of Fusion Pharmaceuticals is .

When does Fusion Pharmaceuticals pay dividends?

Fusion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharmaceuticals?

Fusion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharmaceuticals located?

Fusion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharmaceuticals from 5/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/4/2024.

When did Fusion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/4/2024.

What was the dividend of Fusion Pharmaceuticals in the year 2023?

In the year 2023, Fusion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Fusion Pharmaceuticals pay out the dividend?

The dividends of Fusion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Pharmaceuticals

Our stock analysis for Fusion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.